Governing the Ungovernables: Dual-Use Research of Concern in the Age of Synthetic Biology
Author: Dr. Odongo Oduor Joseph
Tags: Synthetic Biology, DURC, Biosecurity, Governance, Gain-of-Function
Category: Biosafety & Policy
Excerpt: The democratisation of synthetic biology tools has created a governance paradox: the same technologies that promise revolutionary advances in medicine, agriculture, and environmental remediation can, in the wrong hands or under the wrong conditions, enable the creation of biological threats of unprecedented severity. This analysis examines the evolving framework for dual-use research oversight and argues for a new governance architecture adequate to the synthetic biology era.
In 2011, two research groups — one led by Ron Fouchier at Erasmus Medical Centre in Rotterdam, the other by Yoshihiro Kawaoka at the University of Wisconsin-Madison — announced that they had independently engineered variants of the H5N1 avian influenza virus capable of airborne transmission between ferrets. The scientific community reacted with alarm. H5N1 had a case fatality rate in humans of approximately 60%; an airborne-transmissible strain could, in the worst-case scenario, trigger a pandemic of catastrophic proportions. The US National Science Advisory Board for Biosecurity recommended that key methodological details be redacted from the published papers — an unprecedented intervention in the history of scientific publishing.
The Fouchier-Kawaoka controversy was not an isolated incident. It was a harbinger of a governance challenge that has grown more acute with every passing year: how to oversee dual-use research of concern (DURC) in an era when the tools of synthetic biology are becoming cheaper, more powerful, and more widely accessible. This challenge sits at the intersection of scientific freedom, public health security, and international law — and it has no easy answers.
The Synthetic Biology Revolution and Its Discontents
Synthetic biology — the design and construction of new biological parts, devices, and systems, or the redesign of existing natural biological systems for useful purposes — has undergone a transformation in the past two decades that is difficult to overstate. The cost of DNA synthesis has fallen by several orders of magnitude, from approximately $10 per base pair in 2000 to under $0.05 per base pair today. CRISPR-Cas9 gene editing, first demonstrated in human cells in 2013, has made precise genomic modification accessible to undergraduate laboratories. Computational tools for protein design, metabolic pathway engineering, and whole-genome synthesis have advanced from the domain of specialist bioinformatics to user-friendly software platforms.
These developments have democratised biological research in ways that are genuinely transformative. Synthetic biology has enabled the production of artemisinin — a critical antimalarial drug — in engineered yeast, dramatically reducing its cost and improving access in malaria-endemic regions. It has produced novel cancer immunotherapies, sustainable biofuels, and biodegradable plastics. It holds the promise of engineering microorganisms capable of remediating contaminated soils, sequestering atmospheric carbon, and producing nitrogen fertiliser without the energy-intensive Haber-Bosch process.
But democratisation is a double-edged phenomenon. The same tools that empower a graduate student to engineer a biosensor for detecting environmental pollutants also lower the technical barriers to engineering pathogens with enhanced transmissibility, virulence, or resistance to medical countermeasures. The 2022 US National Intelligence Council assessment on biological threats noted that the convergence of synthetic biology, artificial intelligence, and advanced automation was creating a "biosecurity risk landscape" that was qualitatively different from anything that existing governance frameworks were designed to address.
The Architecture of DURC Oversight
The formal architecture of DURC oversight in the United States — the world's most developed national framework — rests on a series of policies developed primarily by the National Institutes of Health and the Department of Health and Human Services. The 2012 US Government Policy for Oversight of Life Sciences Dual Use Research of Concern established a framework for identifying, reviewing, and mitigating DURC involving fifteen categories of high-consequence pathogens and toxins. A companion policy for federally funded research institutions established institutional review requirements and risk mitigation planning obligations.
The 2024 Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential (DURC-PEPP) represented a significant evolution of this framework, introducing the concept of "pathogens with enhanced pandemic potential" as a distinct regulatory category and strengthening requirements for risk-benefit analysis and institutional oversight. As documented by Dousse and Summermatter in Applied Biosafety (2025), the new policy reflects a recognition that the original DURC framework was insufficiently responsive to the rapid pace of synthetic biology innovation.
Yet even the most sophisticated national framework faces fundamental limitations when confronted with the global nature of synthetic biology research. The Biological Weapons Convention (BWC), which prohibits the development, production, and stockpiling of biological weapons, lacks a formal verification mechanism — a gap that has been recognised for decades but never adequately addressed. The Cartagena Protocol on Biosafety addresses transboundary movement of living modified organisms but was not designed to govern research activities. The result is a patchwork of national policies, voluntary guidelines, and international instruments that, as Springer's 2025 analysis of AI and synthetic biology governance noted, constitutes a "dense but misaligned" regulatory landscape.
The Gain-of-Function Debate as Governance Stress Test
No issue has more sharply exposed the limitations of existing DURC governance frameworks than the debate over gain-of-function (GOF) research — experiments that enhance the transmissibility, virulence, or host range of pathogens. The Fouchier-Kawaoka H5N1 experiments catalysed a moratorium on GOF research in the United States from 2014 to 2017, followed by the development of a new P3CO (Potential Pandemic Pathogen Care and Oversight) framework that established an interagency review process for federally funded GOF research.
The COVID-19 pandemic reignited this debate with extraordinary intensity. Questions about the origins of SARS-CoV-2 — specifically, whether it might have emerged from a laboratory conducting GOF-adjacent research — transformed what had been a relatively contained scientific policy discussion into a politically charged controversy with global implications. Regardless of how the origins question is ultimately resolved, the pandemic demonstrated that the governance of high-risk pathogen research has consequences that extend far beyond the laboratory.
The ethical analysis of GOF research, as Michael Selgelid argued in his influential 2016 paper in Science and Engineering Ethics, requires a careful weighing of potential benefits (improved pandemic preparedness, vaccine development, fundamental virology knowledge) against potential harms (laboratory accident risk, information hazard from publication, potential for deliberate misuse). This weighing is genuinely difficult, and reasonable scientists and ethicists disagree about where the balance lies. What is not reasonable is the absence of a rigorous, transparent, internationally coordinated process for conducting this analysis — which is precisely what the current governance landscape fails to provide.
Towards a New Governance Architecture
The governance challenge posed by DURC in the synthetic biology era is not amenable to simple solutions. But several principles can guide the development of a more adequate framework.
Anticipatory governance — the proactive identification and management of emerging risks before they materialise — must replace the reactive, crisis-driven approach that has characterised DURC oversight to date. The history of synthetic biology governance is largely a history of governance catching up to technology after the fact: the Asilomar Conference on recombinant DNA in 1975, the NSABB intervention on H5N1 in 2011, the P3CO framework in 2017. Each intervention was valuable, but each came after the technology had already advanced to a point where the governance challenge was acute. Building anticipatory governance capacity requires sustained investment in technology foresight, regular horizon-scanning exercises, and governance processes that can move at the speed of science.
International coordination is not optional — it is a prerequisite for effective DURC governance. A research activity that is prohibited in one jurisdiction can be conducted in another with minimal regulatory friction; information about dual-use techniques, once published, is globally accessible. Effective governance must therefore be built on international norms, information-sharing mechanisms, and mutual recognition agreements that create a level playing field and prevent regulatory arbitrage. The BWC Review Conference process provides a forum for developing such norms, but it has historically been hampered by geopolitical tensions and the absence of a permanent secretariat with meaningful analytical capacity.
Researcher responsibility must be recognised as a genuine ethical obligation, not merely a compliance requirement. The scientific community has a long tradition of self-governance — from the Asilomar moratorium to the voluntary guidelines of the International Gene Synthesis Consortium — and this tradition must be strengthened and extended to the synthetic biology era. This means embedding biosecurity awareness into scientific education at every level, developing clear professional norms around the communication of dual-use research, and creating institutional cultures in which researchers feel empowered to raise biosecurity concerns without fear of professional consequences.
Transparency and accountability in the governance process itself are essential for maintaining public trust. DURC review processes that operate entirely behind closed doors — even when justified by legitimate security concerns — erode the public confidence that biosafety governance ultimately depends on. Finding the right balance between necessary confidentiality and appropriate transparency is difficult, but it is a challenge that governance institutions must actively engage rather than avoid.
The synthetic biology revolution is not going to slow down. The tools will continue to become cheaper, more powerful, and more widely accessible. The governance challenge will continue to grow more complex. The question is whether the institutions responsible for managing biological risk can develop the frameworks, the capacities, and the international cooperation necessary to govern the ungovernables — or whether they will continue to lag behind the technology until the next crisis forces another reactive intervention. The stakes, measured in potential pandemic casualties and the integrity of the global biosecurity architecture, could not be higher.
Dr. Odongo Oduor Joseph is a molecular microbiologist, biosecurity expert, and AI data informatics specialist. His research spans biosafety governance, synthetic biology risk assessment, and computational approaches to global health security.